The treatment protocol consisted of oral administration of BaSO4 (150 mg) followed one hour later by Ra223 (10 kBq). The biodistribution was determined at 1,2,4,6, and 24 hours after injection. Organs examined included liver, kidney, small intestine, large intestine, spleen, femur and blood. Urine and feces were also collected.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Presented By: Sayaka Hanadate from Toho University and National Institute of Radiological Science, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan
Written By: William Carithers, Lawrence Berkeley National Laboratory
at the 10th International Symposium on Targeted Alpha Therapy (TAT-10) May 31 - June 1, 2017 - Kanazawa, Japan.